Literature DB >> 21254163

Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients.

Zheng Zhang1, Shuye Zhang1, Zhengsheng Zou2, Jianfei Shi1, Juanjuan Zhao1, Rong Fan2, Enqiang Qin2, Baosen Li2, Zhiwei Li2, Xiangsheng Xu1, Junliang Fu1, Jiyuan Zhang1, Bin Gao3, Zhigang Tian4, Fu-Sheng Wang1.   

Abstract

UNLABELLED: Natural killer (NK) cells are abundant in the liver and serve as a major innate immune component against microbial infection. Although NK cells have been implicated in inducing hepatocellular damage in patients with chronic hepatitis virus infections, the roles that hepatic NK cells play in chronic hepatitis B virus (HBV) infections remain obscure. In this study, we comprehensively characterized intrahepatic and peripheral NK cells and investigated their impact on liver pathology in a cohort of HBV-infected individuals; this cohort included 51 immune-activated (IA) patients, 27 immune-tolerant (IT) carriers, and 26 healthy subjects. We found that NK cells expressing NK receptors (activation receptors) preferentially accumulated in the livers of IA patients, in which they were activated and skewed toward cytolytic activity but without a concomitant increase in interferon-γ production, in comparison with those of IT carriers and healthy subjects. Further analysis showed that the livers of IA patients, in comparison with those of IT and healthy subjects, expressed higher levels of interleukin-12 (IL-12), IL-15, and IL-18 in situ and lower levels of IL-10, which in vitro can induce the activation and degranulation of NK cells from healthy individuals. Finally, hepatic NK cells displayed more cytolytic activity than peripheral NK cells, and this was found to be positively correlated with the liver histological activity index and serum alanine aminotransferase levels in these IA patients.
CONCLUSION: In IA patients, hepatic NK cells are activated and preferentially skew toward cytolytic activity, which depends on an imbalanced cytokine milieu and correlates with liver injury during chronic HBV infection.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21254163      PMCID: PMC3767982          DOI: 10.1002/hep.23977

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 2.  Classification of chronic viral hepatitis: a need for reassessment.

Authors:  P J Scheuer
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

Review 3.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

5.  MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs.

Authors:  Giovanni Sitia; Masanori Isogawa; Matteo Iannacone; Iain L Campbell; Francis V Chisari; Luca G Guidotti
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

6.  Genomic analysis of the host response to hepatitis B virus infection.

Authors:  Stefan Wieland; Robert Thimme; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-20       Impact factor: 11.205

7.  Genomic analysis of the host response to hepatitis C virus infection.

Authors:  Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

Review 8.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

9.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

Authors:  M K Maini; C Boni; C K Lee; J R Larrubia; S Reignat; G S Ogg; A S King; J Herberg; R Gilson; A Alisa; R Williams; D Vergani; N V Naoumov; C Ferrari; A Bertoletti
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

10.  Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  K Kakimi; T E Lane; S Wieland; V C Asensio; I L Campbell; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  72 in total

1.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

2.  Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.

Authors:  Nan Meng; Xiao Gao; Wei Yan; Mi Wang; Ping Liu; Xiao-Dan Lu; Shu-Juan Zhang; Ya-Qi Lu; Wang-Xian Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

3.  Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors.

Authors:  Xue-Xiu Zhang; Li-Feng Wang; Lei Jin; Yuan-Yuan Li; Shu-Li Hao; Yan-Chao Shi; Qing-Lei Zeng; Zhi-Wei Li; Zheng Zhang; George Kk Lau; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 4.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

5.  Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection.

Authors:  N Yawata; K J Selva; Y-C Liu; K P Tan; A W L Lee; J Siak; W Lan; M Vania; A Arundhati; L Tong; J Li; J S Mehta; M Yawata
Journal:  Mucosal Immunol       Date:  2015-06-17       Impact factor: 7.313

6.  Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.

Authors:  Q Zheng; Y Y Zhu; J Chen; Y B Ye; J Y Li; Y R Liu; M L Hu; Y C Zheng; J J Jiang
Journal:  Clin Exp Immunol       Date:  2015-04-12       Impact factor: 4.330

Review 7.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

Review 8.  Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon.

Authors:  Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Hepatol       Date:  2015-10-18

9.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

Review 10.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.